Trade

with

Athersys Inc
(NASDAQ: ATHX)
AdChoices
1.32
-0.01
-0.75%
After Hours :
1.30
-0.02
-1.52%

Open

1.34

Previous Close

1.33

Volume (Avg)

136.54k (294.44k)

Day's Range

1.28-1.34

52Wk Range

1.08-4.33

Market Cap.

102.01M

Dividend Rate ( Yield )

-

Beta

1.09

Shares Outstanding

77.28M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 2.44M

    • Net Income

    • -30.74M

    • Market Cap.

    • 102.01M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -994.61

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.09

    • Forward P/E

    • -4.75

    • Price/Sales

    • 34.84

    • Price/Book Value

    • 3.30

    • Price/Cash flow

    • -3.88

      • EBITDA

      • -24.11M

      • Return on Capital %

      • -84.15

      • Return on Equity %

      • -122.97

      • Return on Assets %

      • -84.15

      • Book Value/Share

      • 0.40

      • Shares Outstanding

      • 77.28M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/20/2014
      Buy
        • 1 Year Price Target

        • 6.00

        • Credit Rating

        • -

        • Analysts

        • 2

        • EPS Estimate

        • -0.23

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -32.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -4.72

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -994.61

            • 39.38

            • Net Profit Margin

            • -994.61

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -480.40

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 8.85

              • 2.92

              • Quick Ratio

              • 8.78

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.33

              • 2.21

              • Book Value/Share

              • 0.40

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -3.45

                • 196.08

                • P/E Ratio 5-Year High

                • -16.73

                • 634.30

                • P/E Ratio 5-Year Low

                • -2.48

                • 124.82

                • Price/Sales Ratio

                • 34.84

                • 9.12

                • Price/Book Value

                • 3.30

                • 8.26

                • Price/Cash Flow Ratio

                • -3.88

                • 47.39

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -122.97

                    (-114.30)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -84.15

                    (-68.80)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -121.46

                    (-113.70)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.08

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -24.46M
                  Operating Margin
                  -1,003.16
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -3.88
                  Ownership

                  Institutional Ownership

                  33.80%

                  Top 10 Institutions

                  32.05%

                  Mutual Fund Ownership

                  6.48%

                  Float

                  99.19%

                  5% / Insider Ownership

                  3.76%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • M&G International Specialist Equity

                  •  

                    1,800,000

                  • 0.00

                  • 2.36

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,096,937

                  • 0.00

                  • 1.42

                  • Vanguard Extended Market Index Fund

                  •  

                    776,444

                  • 1.26

                  • 1.00

                  • Vanguard Instl Total Stock Market Index

                  •  

                    353,210

                  • 0.00

                  • 0.46

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    250,029

                  • 0.00

                  • 0.32

                  • iShares Micro-Cap

                  •  

                    219,360

                  • 1.28

                  • 0.27

                  • Munder Micro Cap Equity Fund

                  •  

                    147,877

                  • -3.40

                  • 0.19

                  • Fidelity Spartan® Total Market Idx Fund

                  •  

                    92,903

                  • 0.00

                  • 0.12

                  • EB DL Non-SL Market Completion Fund

                  •  

                    61,489

                  • 203.74

                  • 0.08

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Sabby Management LLC

                  •  

                    4,452,970

                  • -10.94%

                  • 5.78

                  • Arnhold & S. Bleichroeder Advisers, LLC

                  •  

                    3,585,414

                  • +20.10%

                  • 4.64

                  • A M Pappas & Associates LLC

                  •  

                    3,517,900

                  • +27.10%

                  • 4.98

                  • SGM Holdings Corp.

                  •  

                    3,339,900

                  • +18.81%

                  • 4.73

                  • Vanguard Group, Inc.

                  •  

                    2,042,468

                  • +2.30%

                  • 2.64

                  • M&G INVESTMENT MANAGEMENT LTD

                  •  

                    1,800,000

                  • +5.39%

                  • 2.33

                  • Royce & Associates, LLC

                  •  

                    865,000

                  • -6.89%

                  • 1.12

                  • Perceptive Advisors LLC

                  •  

                    601,852

                  • -14.22%

                  • 0.78

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Core

                  Athersys Inc was incorporated in Delaware on October 24, 1995. On June 8, 2007, it merged with a wholly owned subsidiary of BTHC VI, Inc., a Delaware corporation, and, on August 31, 2007, BTHC VI, Inc. changed its name to Athersys, I...morenc. It is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates. The Companys current product development portfolio consists of MultiStem, a patented and proprietary stem cell product that it is developing as a treatment for multiple disease indications, and that is currently being evaluated in two ongoing clinical trials. In addition, it is developing pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, narcolepsy or other forms of excessive daytime sleepiness. Its business obje...morective is to discover, develop and commercialize novel therapeutic products for disease indications that represent areas of clinical need and commercial opportunity. Its partner, Pfizer Inc. is conducting Phase 2 clinical study of MultiStem cells. Myocardial infarction is one of the causes of death and disability in the United States. The Company is engaged in five programs including, Inflammatory Bowel Disease; Ischemic Stroke; Acute Myocardial Infarction; Hematopoietic Stem Cell Transplant / GvHD; Multistem. The Company partners with Pfizer, RTI, Angiotech and Bristol-Myers Squibb. It competes with Stem Cells Inc., Johnson & Johnson, Celgene Corporation, or Celgene, Advanced Cell Technology, Inc. The Company has 36 issued patents; 16 United States and 20 international. The Company and its related programs and the products are subject to government regulations.lessless

                  Key People

                  Dr. Gil Van Bokkelen

                  CEO/Chairman of the Board/Co-Founder/Director

                  John J. Harrington

                  Chief Scientific Officer/Co-Founder/Director/Executive VP

                  Laura K. Campbell

                  CFO/Chief Accounting Officer/Vice President, Divisional

                  Robert Deans

                  Executive VP, Divisional

                  Jack L. Wyszomierski

                  Director

                  • Athersys Inc

                  • 3201 Carnegie Avenue

                  • Cleveland, OH 44115-2634

                  • USA.Map

                  • Phone: +1 216 431-9900

                  • Fax: +1 216 361-9495

                  • athersys.com

                  Incorporated

                  1995

                  Employees

                  56

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: